Form 4: Aclaris Therapeutics Interim CEO Neal Walker Reports Share Transactions

Interim President and CEO of Aclaris Therapeutics, Neal Walker, reports acquisition and disposal of common stock and restricted stock units on March 1, 2024.

Summary

• On March 1, 2024, Neal Walker, Interim President and CEO of Aclaris Therapeutics, reported transactions involving Aclaris Therapeutics, Inc. [ACRS] common stock.
• Walker acquired 9,466 shares of common stock through the vesting of restricted stock units.
• Simultaneously, Walker disposed of 3,223 shares at a price of $1.24 to cover tax withholding obligations related to the vesting of these restricted stock units.
• Following these transactions, Walker directly owns 1,279,445 shares of Aclaris Therapeutics common stock and 132,534 restricted stock units.
• A power of attorney was executed on February 28, 2024, granting Kevin Balthaser, Matthew Rothman, Mark Ballantyne, David Brinton, and Robin Lee the authority to file SEC forms on Walker's behalf.

Sentiment

Score: 5

Explanation: This is a neutral report on stock transactions by an executive, with no inherent positive or negative implications for the company's overall outlook.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives regarding their holdings in the company's stock.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring transparency of insider transactions.
• The transactions reported are typical for executives receiving stock-based compensation.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they represent a small percentage of the total outstanding shares.
• The disclosure provides transparency to shareholders regarding executive compensation and stock ownership.

Key Dates